According to Nguyen et al., nanoparticle therapy containing miR-200c as a PD-L1 inhibitor with a BRAF inhibitor demonstrated significant efficacy in a mouse model of CRC [177]. This evidence concerns the gene CD274 and colorectal carcinoma.